|
...relates class of inverse agonists to the 5-HT2A serotonin receptor, which is thought to be involved in the regulation of sleep architecture and sleep maintenance. These inverse agonists may be useful in pharmaceutical compositions for the treatment of insomnia. APD125, discovered by Arena, is an orally available 5-HT2A receptor modulator covered under the patent. Arena intends to validate the patent in 31 European jurisdictions, including Germany, France, Italy, the United Kingdom and Spain.
On June 30, 2005, Arena announced top-line results from its Phase 1 clinical trial program, which indicated that APD125 was well tolerated at all doses...
NOTE: All illustrations and photos
have been removed from this article.
More articles from BIOTECH Patent News
Nanogen expands patent portfolio in genetic analysis technologies., December 01, 2005
EntreMed to acquire Miikana - acquisition strengthens oncology pipelin..., December 01, 2005
PreMD comments on AtheroGenics' athersclerosis commercialization agree..., December 01, 2005
European patent issued to Bavarian Nordic A/S on vaccine vector., December 01, 2005
Exelixis signs commercial license for the production of paclitaxel and..., December 01, 2005
Looking for additional articles?
Search our database of over 3 million articles.
Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication
name or publication date.
About Goliath
Whether you're looking for sales prospects, competitive information, company
analysis or best practices in managing your organization,
Goliath can help you meet your business needs.
Our extensive business information databases empower business
professionals with both the breadth and depth of credible,
authoritative information they need to support their business
goals. Whether it be strategic planning, sales prospecting,
company research or defining management best practices -
Goliath is your leading source for accurate information.
|
